EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis

Yaning Tian iD, Meixuan Li, Haoyang Hong, Rongfang Feng, Mai Luo, Yumin Xia iD

Clinical and Experimental Dermatology · 2026

DOI: 10.1093/ced/llag242 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Yaning Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Janus Kinase Inhibitors, Pharmacovigilance. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shaanxi Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeted systemic therapies for atopic dermatitis (AD), including biologics and Janus kinase inhibitors, are increasingly used. However, comparative postmarketing evidence on herpetic infection-related safety signals across these therapies remains limited.

Objectives

To compare safety signals of herpetic infections associated with targeted AD therapies using the Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods

FAERS reports (Q2 2017 to Q1 2025) involving dupilumab, abrocitinib, baricitinib or upadacitinib were included if these agents were designated as the primary suspect drug and the indication was AD. Disproportionality analyses using four algorithms were performed to detect signals for overall and virus-specific herpetic events. Subgroup analyses by age, sex and time to onset (TTO) were conducted.

Results

All therapies demonstrated positive signals for herpetic infections. Baricitinib and abrocitinib showed the strongest signals, followed by upadacitinib, whereas dupilumab showed comparatively lower signals overall. Notably, dupilumab demonstrated a herpes simplex virus (HSV) signal comparable with abrocitinib and higher than for upadacitinib, and a signal for eczema herpeticum (EH) was also identified. Signals were generally higher in female patients, except for upadacitinib. Age-stratified analyses showed varying signal patterns across age groups. The median TTO differed between therapies, with an earlier onset for upadacitinib.

Conclusions

Reporting patterns of herpetic infections differ across targeted AD therapies. Disproportionate reporting of HSV and EH with dupilumab warrants further investigation. Differences across sex, age and TTO suggest potential heterogeneity in reporting patterns, which may reflect underlying patient characteristics and reporting behaviours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedJanus Kinase InhibitorsPharmacovigilanceHerpesviridae InfectionsHumansFemaleMalePyrazolesChildPurinesAdultSulfonamidesAzetidinesAdolescentAdverse Drug Reaction Reporting SystemsMiddle AgedHeterocyclic Compounds, 3-RingChild, PreschoolYoung AdultInfantAgedUnited StatesPyrimidines

Substanzen

Antibodies, Monoclonal, HumanizedPyrazolesJanus Kinase InhibitorsbaricitinibdupilumabPurinesSulfonamidesAzetidinesupadacitinibabrocitinib

Autor:innen und Institutionen

  • Department of Dermatology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Xi'an Jiaotong University Health Science Center, Xi'an, China.
  • Core Research Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

ORCID-Profile: Yaning Tian, Yumin Xia

Förderung

  • National Key Research and Development Program of China
  • Shaanxi Health Commission

Zitieren

APA

Tian, Y., Li, M., Hong, H., Feng, R., Luo, M., & Xia, Y. (2026). Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag242

Vancouver

Tian Y, Li M, Hong H, Feng R, Luo M, Xia Y. Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag242

BibTeX
@article{Tian2026,
  author = {Tian, Yaning and Li, Meixuan and Hong, Haoyang and Feng, Rongfang and Luo, Mai and Xia, Yumin},
  title = {Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag242}
}
Kostenlos starten →